What is GeneDx Holdings's cost not yet recognized?

GeneDx Holdings (WGS) reported cost not yet recognized of $0 in Q1 2026.

How has GeneDx Holdings's cost not yet recognized changed year-over-year?

GeneDx Holdings's cost not yet recognized decreased by 100.0% year-over-year, from $400K to $0.

GeneDx Holdings WGS Cost not yet recognized

Cost not yet recognized at other companies

Guardant HealthGH

——

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.89B-24.3%

Enterprise value$1.89B-22.8%

P/S4.3×-3.3×

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's cost not yet recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's cost not yet recognized?: GeneDx Holdings (WGS) reported cost not yet recognized of $0 in Q1 2026.
How has GeneDx Holdings's cost not yet recognized changed year-over-year?: GeneDx Holdings's cost not yet recognized decreased by 100.0% year-over-year, from $400K to $0.